

PUBLISHED VERSION

McAllister, Lauren Joy; Ogunniyi, Abiodun David; Stroehrer, Uwe Horst; Paton, James Cleland. Contribution of a genomic accessory region encoding a putative cellobiose phosphotransferase system to virulence of *Streptococcus Pneumoniae*. PLoS ONE, 2012; 7(2):e32385

Copyright: © 2012 McAllister et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PERMISSIONS

<http://www.plosone.org/static/policies.action#copyright>

3. Copyright and License Policies

Open access agreement. Upon submission of an article, its authors are asked to indicate their agreement to abide by an open access Creative Commons license (CC-BY). Under the terms of this license, authors retain ownership of the copyright of their articles. However, the license permits any user to download, print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and source of the work. The license ensures that the authors' article will be available as widely as possible and that the article can be included in any scientific archive.

Open access agreement: US government authors. Papers authored by one or more US government employees are not copyrighted, but are licensed under a Creative Commons public domain license (CC0), which allows unlimited distribution and reuse of the article for any lawful purpose. Authors should read about CC-BY or CC0 before submitting papers.

Archiving in PubMed Central. Upon publication, PLoS also deposits all articles in PubMed Central. This complies with the policies of funding agencies, such as the NIH in the USA, the Wellcome Trust, and the Research Councils in the UK, and the Deutsche Forschungsgemeinschaft in Germany, which request or require deposition of the published articles that they fund into publicly available databases.

<http://www.plos.org/about/open-access/license/>

LICENCE

The Public Library of Science (PLoS) applies the [Creative Commons Attribution License](#) (CC-BY) to works we publish (read the [human-readable summary](#) or the [full license legal code](#)). Under this license, authors retain ownership of the copyright for their content, but allow anyone to download, reuse, reprint, modify, distribute, and/or copy the content as long as the original authors and source are cited. **No permission is required from the authors or the publishers.**

Appropriate attribution can be provided by simply citing the original article (e.g., Kaltenbach LS et al. (2007) Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration. PLoS Genet 3(5): e82. doi:10.1371/journal.pgen.0030082).

For any reuse or redistribution of a work, users must also make clear the license terms under which the work was published.

This broad license was developed to facilitate free access to, and unrestricted reuse of, original works of all types. Applying this standard license to your own work will ensure that it is freely and openly available in perpetuity.

If you have a question about the Creative Commons License please use this [contact form](#) and choose "General Questions."

6 September 2012

<http://hdl.handle.net/2440/73013>

Contribution of a Genomic Accessory Region Encoding a Putative Cellobiose Phosphotransferase System to Virulence of *Streptococcus pneumoniae*

Lauren J. McAllister, Abiodun D. Ogunniyi, Uwe H. Stroehert, James C. Paton*

Research Centre for Infectious Diseases, School of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia, Australia

Abstract

Streptococcus pneumoniae (the pneumococcus) is a formidable human pathogen, responsible for massive global morbidity and mortality. The ability to utilize carbohydrates in a variety of host niches appears to be integral to pneumococcal pathogenesis. In this study we investigated a genomic island, which includes a ROK family protein, a putative cellobiose phosphotransferase system (PTS) and a putative sulfatase. This accessory region is widespread in the pneumococcus in strains of various serotypes and levels of virulence. We have performed simple bioinformatic analysis of the region and investigated its role *in vivo* in 2 strains with markedly different virulence profiles (WCH206 of serotype 3, ST180; Menzies5 of serotype 11A, ST662). Deleting and replacing the entire island with an antibiotic resistance cassette caused the virulent serotype 3 strain to become attenuated in a murine pneumonia/sepsis model. Further mutants were constructed and used to show that various components of the island contribute significantly to the fitness of WCH206 in a variety of niches of this model, including the nasopharynx, ears and blood, but especially in the lungs. In addition, the island conferred a competitive advantage in nasopharyngeal colonization for the serotype 11A strain, which was essentially avirulent in the pneumonia/sepsis model. The contribution of this island to both pathogenesis and colonization may explain why this accessory region is widespread in the pneumococcus.

Citation: McAllister LJ, Ogunniyi AD, Stroehert UH, Paton JC (2012) Contribution of a Genomic Accessory Region Encoding a Putative Cellobiose Phosphotransferase System to Virulence of *Streptococcus pneumoniae*. PLoS ONE 7(2): e32385. doi:10.1371/journal.pone.0032385

Editor: Dipshikha Chakravorty, Indian Institute of Science, India

Received: November 16, 2011; **Accepted:** January 27, 2012; **Published:** February 21, 2012

Copyright: © 2012 McAllister et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Program Grant 565526 and Project Grant 627142 from the National Health and Medical Research Council (NHMRC) of Australia supported this research. JCP is a NHMRC Australia Fellow. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: james.paton@adelaide.edu.au

† Current address: School of Biological Sciences, Flinders University, Bedford Park, South Australia, Australia

Introduction

Streptococcus pneumoniae (the pneumococcus) is a formidable pathogen, which is the principal bacterial cause of pneumonia, sepsis and otitis media (OM), and responsible for more deaths worldwide than any other bacterium. The polysaccharide capsule is a *sine qua non* of virulence and defines the serotype of which there are over 90 identified to date. Nevertheless, additional non-capsular factors also play an integral role in pathogenesis. *S. pneumoniae* carries a large number of sugar transporters, which have been proposed to help it occupy unique *in vivo* micro-environmental niches [1]. However, little is known about pneumococcal carbohydrate utilization and metabolism in these environments [2]. Sugar transporters have been identified during signature-tagged mutagenesis virulence factor screens [3,4,5,6], and several defined transporter mutants have been shown to be attenuated *in vivo* [2,7]. This indicates that despite the large number of sugar transporters, the removal of even one can have a measurable impact on virulence.

Some systems appear to be functionally conserved in the pneumococcus, such as the well-characterized neuraminidase NanA or the Sus and Scr sucrose utilization systems, although there can be sequence variation between strains [2,8]. There are also carbohydrate utilisation systems encoded on accessory regions

that are not uniformly distributed amongst strains [1,9,10,11,12]. McKessar and Hakenbeck have previously described an accessory region (the *cel* locus) containing a cellobiose phosphotransferase system (PTS) [13], whose components were also identified during a signature-tagged mutagenesis study using an otitis media model [6]. In this study we examined an alternative accessory region harbouring a putative cellobiose phosphotransferase system (PTS), which has been previously described as being absent in D39 and TIGR4 and hypothesised to be involved in virulence [14,15,16,17,18]. Despite its absence in D39 and TIGR4, this PTS was present in four distinct serotype 3 isolates (Menzies11 and Menzies17 of ST458, and WCH206 and WCH207 of ST180), which were highly virulent in a mouse sepsis model, but absent in the significantly less virulent serotype 3 strain WU2 (ST378) [18]. However, as with the *cel* locus, we found that this system is present in a wide range of pneumococcal isolates belonging to diverse serotypes (over 80% of those tested), including unrelated avirulent isolates of serogroup 11 [18]. The PTS is part of a larger 10 kb island (see Fig. 1), which also encodes a ROK family protein, a putative sulfatase (arylsulfatase) and a putative sulfatase modifying factor, as well as a couple of hypothetical proteins [14,16,17,18]. The ROK family comprises transcriptional repressors, ORFs of unknown function and sugar kinases in bacteria, and includes a xylose repressor from *Bacillus subtilis*, a *N*-acetylglucosamine




Figure 1. Organisation of the PTS island and location of mutagenesis deletions. Genes sph1922/spnoxc15810 – sph1930/spnoxc15890 of *S. pneumoniae* Hungary 19A-6 and OXC141 (serotype 3, ST180), which are present in our strains WCH206 and Menzies5, are represented. The locations of the various deletion mutants constructed in this study are indicated. doi:10.1371/journal.pone.0032385.g001

[GlcNAc] repressor, *nagC*, from *Escherichia coli*, and a fructose kinase from *S. mutans* [19]. In contrast, sulfatases are highly conserved across eukaryotes and prokaryotes and are believed to be used by prokaryotes to hydrolyse sulphate ester groups from proteoglycans, glycosaminoglycans (GAGs) and choline sulphate [20]. They are normally associated with a sulfatase-modifying factor [21], which is required to catalyse the post-translational activation of the sulfatase, an unusual feature for prokaryotic proteins [22]. There are many other pneumococcal sugar transporters also associated with hydrolases, but this particular system is interesting in that some strains, including G54 and serotype 3 isolates of ST458 (Menzies11 and Menzies17), have a deletion removing the sulfatase, as well as parts of the sulfatase modifying factor and the last gene of the PTS operon [18]. Due to the prevalence of this island and its interesting annotation, in this study we have constructed mutants of the island in two distinct *S. pneumoniae* genetic backgrounds and investigated the impact on phenotype *in vivo*.

Results

Bioinformatic analysis

We commenced by performing simple bioinformatic analysis of the various components of the AR. We observed that the ROK family protein does not appear to have the characteristic binding motif described by Titgemeyer et al. (1994), yet its size suggests it is more likely to be a repressor than a kinase [19]. A BLAST-p search revealed a NagC domain, but no DNA binding motif. In contrast, when the amino acid sequence of NagC from *E. coli* K12 (NC_000913) was examined, a MarR (repressor of the multiple drug resistance operon) family motif was detectable at the N-terminus. Interestingly, a Pfam search using the same sequences identified a MarR family motif in both proteins at the N-terminus, which was a significant match for NagC, but insignificant for the pneumococcal ROK family protein. HHPred indicated there is helix-turn-helix domain at the N-terminus of the pneumococcal ROK family protein and the best 3 matches, which had probabilities of 100 and E and P values of 0, were the well-characterised Mlc repressor of *E. coli*, which is homologous to NagC, an Mlc homolog of *Vibrio cholerae* and a putative N-acetylmannosamine repressor of *Thermotoga maritima* (also annotated as N-acetylglucosamine kinase). Interestingly, Pfam searches using the amino acid sequences of these 3 matches identified insignificant matches for the iron dependent repressor family, the MarR family and the MarR 2 family, respectively.

A BLAST-p search of various components of the putative cellobiose PTS revealed it belongs to the Lactose-N,N'-Diacetylchitobiose β -glucoside (Lac) family (Family 4.A.3), which is a family of β -glucoside, cellobiose and chitin disaccharide

(N, N'-diacetylchitobiose) transporters. The hypothetical protein associated with the PTS components has been annotated as PEP phosphonomutase-like protein in some pneumococci. A HHPred search revealed the highest homology with inosine-5'-monophosphate dehydrogenase, GMP reductase 2 and most interestingly, N-acetylmannosamine-6-phosphate 2-epimerase 2 (probabilities greater than 99%).

Finally, HHPred analysis of the sulfatases identified homology (probability of 100, P and E values of 0) with other sulfatases as expected, as well as a phosphonate monoester hydrolase (from *Rhizobium leguminosarum*) and an alkaline phosphatase (from Antarctic bacterium TAB5). Interestingly, the hypothetical protein encoded adjacent to the sulfatase-modifying factor has a significant Pfam match with the TauE family (sulfite exporter TauE/SafE).

Mutational analysis

To examine the phenotypic contribution of the genomic island encoding the putative cellobiose PTS, an in-frame, deletion-replacement mutant in the serotype 3 OM isolate WCH206 (ST180), designated WCH206 Δ Island, was constructed by removing and replacing the entire island with an erythromycin resistance cassette attached to the promoter of the serotype 2 capsule locus, as described in the Materials and Methods and shown in **Figure 1**. This erythromycin resistance cassette has been previously used to construct nonpolar mutants of the capsular biosynthesis locus in D39 [23]. The orientation of the genes of the accessory region necessitated the inclusion of a promoter to allow expression of the erythromycin resistance gene, which is why the cassette was amplified from the mutant D39-ABAe [23] to include the capsule locus promoter. Following confirmation of the mutation by sequencing, opaque variants were selected for all experiments, except the biofilm assay and colonisation competition study for which transparent pneumococci were preferred.

Initially, the mutant was examined for alterations in both planktonic and biofilm growth, as well as sugar fermentation. The numbers of biofilm-forming and planktonic bacteria were determined for WCH206 and WCH206 Δ Island on days 1, 2, 4 and 7 in triplicate samples grown in 0.5 \times BHI. No significant differences in the growth characteristics or numbers of planktonic or biofilm-associated bacteria were observed at the time points examined (**Figure 2**). Fermentation of cellobiose by WCH206 and WCH206 Δ Island grown in THY to mid-exponential phase was also investigated in two independent experiments, using the purple broth assay with sucrose as the positive control (see Materials and Methods). There was no difference between wild-type and mutant in their capacity to ferment cellobiose, although the colour change observed was less than that for sucrose (data not




Figure 2. *In vitro* fitness of WCH206 Δ Island. Biofilm and planktonic growth of WCH206 and WCH206 Δ Island in 0.5 \times BHI was measured over a 7 day period. Median bacterial numbers are indicated by black, horizontal bars.
doi:10.1371/journal.pone.0032385.g002

shown). Shafeeq et al. (2011) used M17 media to investigate the *cel* locus [24]. We cultured the mutant and wild-type in M17 supplemented with 5% (w/v) glucose, cellobiose or lactose. The previous observation that the PTS belongs to the Lactose-N, N'-diacetylchitobiose β -glucoside (Lac) family was the reasoning behind the inclusion of lactose. Although removing the island did not retard growth in these media (data not shown), growth in the cellobiose supplemented media was very poor compared to the other two media and neither strain grew over A_{600} 0.3 in the cellobiose supplemented media when the culture was started from

BA. In addition to the growth assays, a sulfatase assay was performed using the WCH206 and WCH206 Δ Island strains with 4-methylumbelliferyl sulfate as the substrate and limpet sulfatase as the positive control [25]. However, no activity was detectable under the conditions used in this study, even when undiluted lysate was used. The limpet sulfatase was still capable of cleaving 4-methylumbelliferyl sulfate when added to lysate of WCH206 suggesting there were no inhibitors of sulfatase activity present in the lysate.

Effects on virulence were then assessed using i.p. and pneumonia/sepsis murine models. In a direct i.p. (sepsis) challenge model, the median survival time of mice challenged with WCH206 Δ Island was not significantly different from that for mice challenged with the otherwise isogenic wild-type strain (Figure 3A). As subtle differences in virulence could be masked due to host-to-host variation, we then compared the mutant and wild-type in a mixed infection model (i.p. competition), and found the mutant was significantly attenuated at 48 h post-infection ($P=0.0252$) (Figure 3B). In the pneumonia/sepsis model, where mice were inoculated intranasally (i.n.) under anaesthetic, there was a significant increase in the median survival time for mice infected with the WCH206 Δ Island mutant compared to the wild-type ($P<0.001$) (Figure 4). Taken together, the results from the i.p and i.n. studies suggest that the genomic island encoding the PTS system plays a significant role in pneumonia and sepsis.

The ability of WCH206 Δ Island to colonize the nasopharynx of mice was also examined. Mice were inoculated intranasally without anaesthesia and the nasopharynx was washed and nasopharyngeal tissue removed and homogenized 1, 2, 4 and 7 days post-inoculation. Data from the nasopharyngeal wash and homogenate were combined. The mutant was found to be significantly attenuated compared to wild-type WCH206 strain on day 1; $\log_{10}CI$ values were less than 0 on days 2 and 4 as well, but this did not reach statistical significance (Figure 5A). As serogroup 11 strains had previously been found to colonize at higher numbers on days 1 and 2 post-inoculation than serotype 3 strains in this model [18], we also constructed an island deletion replacement mutant in the serotype 11A carriage isolate Menzies5 (ST662) using the same method. Replacing the entire island with an erythromycin cassette downstream of a capsule locus promoter also did not affect *in vitro* growth of this strain, including in M17 medium supplemented with lactose and cellobiose, although both strains grew poorly in the presence of cellobiose (data not shown). Infection with a mixed culture (Menzies5 and Menzies5 Δ Island) was performed and the competitive indices in the nasopharynx calculated. The mutant was significantly attenuated compared to the wild-type at all time points for Menzies5 (Figure 5B).

Since the mutants described above had deletions of the entire island, we sought to determine which individual components of this region were responsible for the attenuation. For this purpose, non-polar deletion replacement mutants of the various components were constructed using the previously described erythromycin resistance cassette without the inclusion of the D39 capsule locus promoter. The first mutation was a deletion of the ROK family protein, the second was of the putative cellobiose PTS and associated hypothetical protein, and the third was of the sulfatase and the sulfatase modifying factor genes (see Figure 1). Mutants were constructed for both Menzies5 and WCH206, but the mutants in Menzies5 were not ultimately used for any animal work. However, due to the low transformability of WCH206 and the conservation of the genes in the accessory region and flanking areas, the erythromycin replacement mutations were amplified from the Menzies5 mutants and introduced to competent




Figure 5. Fitness of Δ Island in the nasopharynx over a 7 day period. CD-1 mice were inoculated i.n. without anaesthesia with 2×10^7 CFU/mouse of a combination of WCH206 and WCH206 Δ Island (serotype 3) at a ratio of 1:4 (panel A) or 1.5×10^6 CFU/ml of a combination of Menzies5 and Menzies5 Δ Island at a ratio of 9:7 (panel B). The \log_{10} CIs were calculated on days 1, 2, 4 and 7 for the nasopharynx (nasopharyngeal tissue and wash combined). The neutral value (0) is indicated by a broken, horizontal line and the mean \log_{10} CIs are indicated by black, horizontal bars. \log_{10} CI values under 0 indicate that the mutant is less fit than the respective wild-type. One sample t-tests were used to compare the mean \log_{10} CI of each group to 0: *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$. doi:10.1371/journal.pone.0032385.g005

of serotype 3 and the less virulent serotype 3 strain WU2 [18]. In the present study, we have examined the fitness of PTS island mutants in various *in vivo* models. These studies were carried out using mutants of two unrelated type 3 (ST180) and type 11A




Figure 6. *In vitro* expression of the putative cellobiose PTS and sulfatase genes in WCH206 Δ ROK. Data were calculated using the $2^{-\Delta\Delta CT}$ method with 16s rRNA acting as an internal control and represent the fold difference between [mRNA] in WCH206 Δ ROK relative to WCH206. Error bars represent the 95% confidence interval. In addition, the fold difference in [mRNA] of the first PTS IIC component and sulfatase (annotated as CG5Sp3B571_03497 and CG5SpB571_3467 in Sp3-B571 [NCBI RefSeq: ZP_01817543.1]) in relation to 16s rRNA (internal control) was calculated and compared between mutant and wild-type using an unpaired t-test (*, $P < 0.05$; **, $P < 0.01$). doi:10.1371/journal.pone.0032385.g006

(ST662) clinical isolates, with markedly different virulence profiles. Initially the entire island was replaced with an erythromycin resistance cassette in the serotype 3 strain WCH206 (ST180), which is highly virulent in our i.p. and pneumonia/sepsis models. In this background, deleting the island did not have a negative impact on the ability to grow or form biofilms in standard laboratory media. We also could not demonstrate differences in the ability to ferment cellobiose or to grow in cellobiose-supplemented M17 medium, as well as to grow in lactose-supplemented medium, although we found growth and fermentation to be poor in the presence of cellobiose in contrast to other sugars. Lack of a sugar uptake defect phenotype could be attributable to the presence of other complementary PTSs, such as that described by McKessar and Hakenbeck [13]. Similarly, a biochemical phenotype could not be assigned to the putative sulfatase mutant.

As the Δ Island mutant did not demonstrate any *in vitro* growth defects, the behaviour of the mutant and wild-type were subsequently examined *in vivo*. When WCH206 and WCH206 Δ Island were compared in two virulence models, survival time increased significantly for mice inoculated with the mutant in the pneumonia-sepsis model but not the i.p. model (Figures 3A and 4). However, when the mutant and wild-type were tested in the more sensitive i.p. competition model, the mutant was isolated less frequently from the blood 2 days after inoculation (Figure 3B). In addition to virulence, colonization was also investigated. A Δ Island mutant of the low-virulence serotype 11A strain Menzies5 (ST662) was also examined, as serogroup 11 strains are better colonizers than type 3 in the i.n. model [18]. WCH206 Δ Island was attenuated significantly in the nasopharynx on day 1 relative to the




Figure 7. Competitiveness of various Island mutants in the pneumonia/sepsis model. Data are combined from duplicate experiments. Mice were inoculated with approximately 3×10^7 CFU/mouse of a combination of WCH206 and either WCH206 Δ ROK, Δ PTS, Δ Sulfatase or Δ Island, at average input ratios of 1.75, 0.5, 1.65 and 1.45, respectively. The CIs were calculated on days 1, 2 and 3 for the nasopharynx (nasopharyngeal tissue and wash combined), lungs, blood and ears, and the mean \log_{10} CIs are indicated by black, horizontal bars. The neutral value is 0 (indicated by a broken, horizontal line). One sample *t*-tests were used to analyze the data (hypothetical value=0): *, $P < 0.05$, **, $P < 0.01$, ***, $P < 0.001$. doi:10.1371/journal.pone.0032385.g007

wild-type; \log_{10} CI values were less than 0 on days 2 and 4 as well, but this did not reach statistical significance (Figure 5A). However, in the Menzies5 background, the mutant was significantly less fit in the nasopharynx at every time point. These results suggest that the island plays a significant role in colonization of both strains and invasive disease caused by WCH206 (Figure 5B).

In an attempt to attribute the virulence defect of Δ Island mutants to individual genes, mutants of the ROK family protein, PTS operon and sulfatase/sulfatase modifying factor were constructed in WCH206. Again there was no impact on growth, but removing the ROK family protein resulted in increased sulfatase and PTS transcription. Bioinformatic analysis of the ROK family protein had previously suggested it was more likely to be a repressor than a kinase. These results are consistent with the recent demonstration that the role of the transcriptional regulator CelR encoded on the pneumococcal *cel* locus (another accessory region), is to activate expression of both the cellobiose PTS and 6-phospho- β -glucosidase of this locus [24]. In our study, the impact on the respective protein levels is not known and it may be that there is also post-translational control of expression. The loss of the PTS and sulfatase presumably impacts the ability of WCH206 to utilize their substrate(s). However, carbon catabolite control is essential to the fitness of bacteria, as carbohydrates must be utilized in preferred order for optimal growth. Therefore, loss of repression of these genes could also be detrimental to fitness. Previously, loss of the pneumococcal lactose-inducible β -galactosidase repressor RegM (also known as catabolite control protein A [CcpA]) has been shown to result in decreased fitness *in vivo* [26,27].

A 3 day competitive study was conducted with the various WCH206 mutants using the pneumonia/sepsis model and the results suggested the island is important in a variety of niches, particularly the lungs, where there was statistically significant attenuation for all mutants at each time point (Figure 7). Attenuation was observed for 3 out of 4 mutants in the nasopharynx over the 3 day period, adding further evidence for the island playing a role in nasopharyngeal fitness. Furthermore, this accessory region may also play a role in otitis media, as the majority of mutants were significantly attenuated in the ears by day 3. With regard to the impact of the various mutations on development of bacteremia, it is possible that diminished ability to colonize lung tissue could limit translocation into the blood and hence the level of bacteremia. Nevertheless, the *i.p.* competition study indicates that the island has an additional impact on sepsis over and above lung colonization and lung-blood translocation. This could not be correlated with survival, however, as mice inoculated *i.p.* with WCH206 Δ Island did not survive significantly longer than those challenged with wild-type (Figure 3A). Overall, the pneumonia/sepsis competition study demonstrates that multiple components of the island contribute to fitness in the various niches. This includes the putative sulfatase, even though there are some *S. pneumoniae* strains, which carry a variant of the island with a deletion in the putative sulfatase. Unfortunately, our ST458 isolates with this deletion were not transformable *in vitro*, so we were unable to assess the impact in this genetic background. It is possible that there is another hydrolase compensating for the loss of the putative sulfatase or the incomplete accessory region still gives a competitive advantage in these particular strains.

The results of this study show that despite the large number of sugar transporters in the pneumococcal genome, the removal of even one sugar utilization system can have an impact on virulence. Little is known about the *in vivo* substrates of many of the putative pneumococcal sugar transporters, although the hydrolases of two putative pneumococcal fucose operons have been recently shown to target different blood group antigens [28]. The competitive advantage conferred by the PTS island in a variety of niches suggests the substrates of the putative cellobiose PTS and putative sulfatase of this study are present in multiple *in vivo* niches. The bioinformatic analysis conducted in this study adds further weight to the likely function of the PTS as a sugar transporter. While it is yet to be determined whether the PTS and putative sulfatase work together, many host sugars undergo modifications, such as sulfation [29,30,31]. It is interesting that the PTS belongs to the chitin disaccharide transporter family, as although chitin is found in the outer covering of insects and crustaceans, it is made of GlcNAc [32]. The homology of the ROK family protein to a putative N-acetylmannosamine repressor and that of the hypothetical protein associated with the PTS components to N-acetylmannosamine-6-phosphate 2-epimerase is also of interest.

Overall, the results of this study show that the pneumococcal genomic island encoding the putative cellobiose PTS confers a competitive advantage in both passive colonization and active invasion models. This is not unexpected given that this region is found in a wide variety of pneumococcal serotypes and STs, including isolates with markedly differing virulence profiles. However, the PTS island is not essential for virulence, and as the island is also found in avirulent strains, the importance of the system in pathogenesis ultimately depends on the strain background. Thus, accumulation of multiple beneficial accessory regions, such as the one described in this study, rather than carriage of any single specific region, is likely to determine the human virulence characteristics of *S. pneumoniae* isolates.

Materials and Methods

Ethics statement

All animal experiments were approved by the Animal Ethics Committee of the University of Adelaide (Project Number: S- 86-2006), and complied with the Australian code of practice for the care and use of animals for scientific purposes (7th Edition 2004) and the South Australian Animal Welfare Act 1985. Written consent was obtained for studies of human specimens and ethics approval was obtained from the Human Research Ethics Committee of the Menzies School of Health Research and Department of Health and Families.

Bacterial strains and growth conditions

The middle ear isolate WCH206 (serotype 3, ST180), nasopharyngeal isolate Menzies5 (serotype 11A, ST662) and the mutant D39-AB Δ e have been described previously [18,23]. *S. pneumoniae* strains were grown in THY (Todd-Hewitt broth [Oxoid, Basingstoke, United Kingdom] supplemented with 1% BactoTM yeast extract [Beckton, Dickinson and Company, Franklin Lakes, NJ, USA]), serum broth (10% [v/v] donor horse

serum in nutrient broth), brain heart infusion (BHI) broth [Oxoid], M17 broth [Oxoid] supplemented with 5% (w/v) glucose (Ajax Finechem, Sydney, Australia), lactose (Ajax Finechem) or cellobiose (Sigma-Aldrich, St. Louis, MO, USA), or on blood agar (BA) plates at 37°C in 95% air and 5% CO₂. Erythromycin (Ery; Roche, Mannheim, Germany), gentamicin (Sigma-Aldrich) and optochin (Sigma-Aldrich) were added at concentrations of 0.2 µg/ml, 5 µg/ml and 5 µg/ml, respectively, where appropriate. Pneumococci were transformed using complete transformation medium (CTM) [26,33]. Sugar fermentation assays were carried out using BBL™ Purple Broth Base (Beckton, Dickinson and Company) essentially as previously described [13]. Static Biofilm assay was performed as described previously [34], except that 0.5×BHI was used in place of THY.

DNA manipulations

Overlap extension PCR was used to construct mutants [35,36]. The primers J214 and J215 [37] were used to amplify the erythromycin resistance gene (*ery*) from D39-ABΔe [23]. For ΔIsland mutants, Pcps F (5'GGTTCGCGGGAAGTCTACTAAG3') was used in place of J215 to include the *cps2* promoter. WCH206 ΔIsland and MSHR5 ΔIsland were constructed using the primers Pcps/sph1930/31 (5'CTTAGTAGACTTCCCGGACACCTATCTCCCTTTTTCACAA TGTATAG3'), sph1932 (5'CCCTATATCATGGCTGGTGACC3'), J215/sph1920/21 (5'CGGGAGGAAATAATTCTATGAGGAAAGCAAACAGCCTTGAAATCAAT) and sph1914 (5'CTAATTCAGTCCAACTTCCAGTTC3'). WCH206 ΔROK was constructed using the primers J214/sph1930 (5'TTGTTTCATGTAATCACTCCTTAG TTGTCAGATTCTTAAAATCCTAT3'), G54 spn02109 (5'CCCTGTGCCTCTCTTGT CAACA3'), J215/sph1930 (5'CGGGAGGAAATAATTCTATGAGACATTTAA-TAA ATAGGCTAAAAAGAGG3') and sph1932 (5'CCCTATATCATGGCTGGTGACC3'). WCH206 ΔPTS was constructed using the primers J214/sph1929 (5'TTGTTTCATGTAA TCACTCCTTCAAATATATTTTATTATCAAAA GT-TATCAATTA3'), sph1930 (5'GTGCGGCTGTAAAATCAT-TGTAAG3'), J215/sph1925 (5'CGGGAGGAAATAA TTCT-ATGAGTTGCGTTTTTTTGTGATAAAAATAGAAAATAGA3') and sph1924a (5'GGGGATTTAATGGAGCATGTGGT3'). WCH206 ΔSulfatase was constructed using J214/sph1924 (5'TTGTTTCATGTAATCACTCCTTCAATATGGCAAAGA-GG CACAAGAA 3'), mRNA sph1925 PTS IIC R (see below), J215/sph1923 (5'CGGGAG GAAATAATTCTATGAGAAAA-AGTGGTTGAGATTATTTATTTT3') and sph1919 (5'AGT-TGCCGAAGACGCTAAAGACG3'). All primers were purchased from Sigma-Aldrich. PCR reactions were carried out using the Expand™ Long Template or High Fidelity PCR Systems (Roche Diagnostics) and an Eppendorf Mastercycler (Eppendorf, Hamburg, Germany). Mutations were confirmed by sequencing using the primers J257 (5'TTAAATGCCCTTACCTGTTCC3') and J258 (5'GAAGCTATATACGTACTTTG TTTC3'). DNA sequencing reactions were carried out using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, California, USA).

RNA analysis

Duplicate cultures in BHI were inoculated from BA plate cultures of each strain and grown to mid-exponential phase. RNA was isolated and purified from bacterial pellets with acid-phenol:chloroform:isoamyl alcohol (125:24:1; pH 4.5, Ambion, Austin, TX., USA) essentially as described previously [38,39]. Differences in gene transcript levels was assessed by real-time RT-PCR on a Rotorgene RG-2000 (Corbett Research, Mortlake, NSW, Australia) using the Invitrogen SuperScript™ III Platinum® SYBR® Green One-Step

qRT-PCR kit. A primer set specific for 16S rRNA (mRNA spd0016 16s F 5'GAGCTTGCTTCTCTGGATGAGTTG3', mRNA spd0016 16s R 5'GTGATGCAAGTGCACCTTT-TAAGC3') was used as internal controls for data normalization. Transcripts of the cellobiose PTS were measured using mRNA sph1929 PTSIIC F (5'ACCTCCCAAAGCTACTTGGAGC-AAT3') and mRNA sph1929 PTSIIC R (5'GATGGTGTTC-CACCAGCAGTATCT3'). Transcripts of the sulfatase were measured using mRNA sph1924 sulfatase F (5'CAATA-AAGCTGCCCTAGCAGGAA C3') and mRNA sph1924 sulfatase R (5'GATCAAATGAGAGCAGACGCCTTA3'). Quantitative fold differences for each transcript were determined using the 2^{-ΔΔCT} method [40].

Virulence and pathogenesis studies

Each animal experiment used outbred 5–6 week old CD-1 (Swiss) mice and was approved by the Animal Ethics Committee of the University of Adelaide. For intraperitoneal (i.p.) and pneumonia/sepsis models, opaque variants were cultured in SB to approximately 1×10⁸ CFU/ml (A₆₀₀=0.16), followed by dilution in sterile SB to the appropriate challenge dose [18,41]. I.p. challenge was performed by injecting mice i.p. with 100–200 µl of inoculum. Mice in the pneumonia/sepsis study were anesthetized with Nembutal (pentobarbitone sodium, Rhone-Merieux) and challenged intranasally (i.n.) with 50 µl of inoculum, as previously described [18,38,39]. The actual challenge doses were determined retrospectively by plating on BA with or without antibiotic selection, as appropriate. For survival studies, mice were monitored closely over a 3 week period following challenge for signs of disease and the survival time of each mouse was recorded. Inoculation of the mice in the i.p. and pneumonia/sepsis competition studies was performed as for the former studies, but a combination of wild-type (Ery^s) and mutant (Ery^r) was used. For the i.n. colonization competition study, transparent phase bacteria were grown in THY to mid-logarithmic phase (A₆₀₀ = 0.5) [18,41]. Mutant (Ery^r) and wild-type (Ery^s) cultures were then concentrated 10-fold, combined, and 10 µl was used to inoculate each mouse i.n. without anaesthesia. For all competition studies, the exact challenge doses and ratio of mutant to wild-type (input ratio) was determined retrospectively by duplicate plating on BA and BA-Ery. Mice were sacrificed by CO₂ asphyxiation and nasal wash, ear wash, nasal tissue, lung, and blood samples were taken where appropriate and processed as previously described [18,38,39,41]. Samples were plated onto BA and BA-Ery to determine the ratio of mutant to wild-type (output ratio) for each niche at each time point. Competitive Index (CI) was calculated as output ratio/input ratio.

Sulfatase assay

The assay was conducted using 4-methylumbelliferyl sulfate potassium salt (Sigma-Aldrich) and limpet sulfatase (Sigma-Aldrich) as a positive control, as previously described [25], with the exception that bacteria were grown in BHI and lysed by either a French pressure cell (SLM Instruments, Urbana, IL, USA) operated at 12,000 psi or with 0.1% (w/v) sodium deoxycholate (BDH Biochemicals, Poole, United Kingdom).

Bioinformatic analysis

In this study, the sequence of the accessory region encoding a putative cellobiose PTS was taken from either *Streptococcus pneumoniae* Hungary19A-6 (CP000936.1; nucleotides 1784680–1794642) or OXC141 (FQ312027.1; nucleotides 1602906–1612886). BLAST (basic local alignment search tool) analysis was performed through the websites of the National Center for Biotechnology Information

(NCBI) and the Transporter Classification Database (TCDB) [42,43]. Searches of the Pfam database (version 25.0) were also performed, as well as on the HHPred server [44,45].

References

- Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, et al. (2001) Complete genome sequence of a virulent isolate of *Streptococcus pneumoniae*. *Science* 293: 498–506.
- Iyer R, Camilli A (2007) Sucrose metabolism contributes to in vivo fitness of *Streptococcus pneumoniae*. *Mol Microbiol* 66: 1–13.
- Hava DL, Camilli A (2002) Large-scale identification of serotype 4 *Streptococcus pneumoniae* virulence factors. *Mol Microbiol* 45: 1389–1406.
- Lau GW, Haataja S, Lonetto M, Kensit SE, Marra A, et al. (2001) A functional genomic analysis of type 3 *Streptococcus pneumoniae* virulence. *Mol Microbiol* 40: 555–571.
- Polissi A, Pontiggia A, Feger G, Altieri M, Mottl H, et al. (1998) Large-scale identification of virulence genes from *Streptococcus pneumoniae*. *Infect Immun* 66: 5620–5629.
- Chen H, Ma Y, Yang J, O'Brien CJ, Lee SL, et al. (2007) Genetic requirement for pneumococcal ear infection. *PLoS One* 3: e2950.
- Embry A, Hinojosa E, Orihuela CJ (2007) Regions of Diversity 8, 9 and 13 contribute to *Streptococcus pneumoniae* virulence. *BMC Microbiol* 7: 80.
- King SJ, Whatmore AM, Dowson CG (2005) NanA, a neuraminidase from *Streptococcus pneumoniae*, shows high levels of sequence diversity, at least in part through recombination with *Streptococcus oralis*. *J Bacteriol* 187: 5376–5386.
- Bruckner R, Nuhn M, Reichmann P, Weber B, Hakenbeck R (2004) Mosaic genes and mosaic chromosomes-genomic variation in *Streptococcus pneumoniae*. *Int J Med Microbiol* 294: 157–168.
- Silva NA, McCluskey J, Jefferies JM, Hinds J, Smith A, et al. (2006) Genomic diversity between strains of the same serotype and multilocus sequence type among pneumococcal clinical isolates. *Infect Immun* 74: 3513–3518.
- Obert C, Sublett J, Kaushal D, Hinojosa E, Barton T, et al. (2006) Identification of a Candidate *Streptococcus pneumoniae* core genome and regions of diversity correlated with invasive pneumococcal disease. *Infect Immun* 74: 4766–4777.
- Blomberg C, Dagerhamn J, Dahlberg S, Browall S, Fernebro J, et al. (2009) Pattern of accessory regions and invasive disease potential in *Streptococcus pneumoniae*. *J Infect Dis* 199: 1032–1042.
- McKessar SJ, Hakenbeck R (2007) The two-component regulatory system TCS08 is involved in cellobiose metabolism of *Streptococcus pneumoniae* R6. *J Bacteriol* 189: 1342–1350.
- Oggioni MR, Pozzi G (2001) Comparative genomics for identification of clone-specific sequence blocks in *Streptococcus pneumoniae*. *FEMS Microbiol Lett* 200: 137–143.
- Shen K, Gladitz J, Antalis P, Dice B, Janto B, et al. (2006) Characterization, distribution, and expression of novel genes among eight clinical isolates of *Streptococcus pneumoniae*. *Infect Immun* 74: 321–330.
- Forbes ML, Horsey E, Hiller NL, Buchinsky FJ, Hayes JD, et al. (2008) Strain-specific virulence phenotypes of *Streptococcus pneumoniae* assessed using the Chinchilla laniger model of otitis media. *PLoS One* 3: e1969.
- Croucher NJ, Walker D, Romero P, Lennard N, Paterson GK, et al. (2009) Role of conjugative elements in the evolution of the multidrug-resistant pandemic clone *Streptococcus pneumoniae* Spain23F ST81. *J Bacteriol* 191: 1480–1489.
- McAllister IJ, Ogunniyi AD, Strocher UH, Leach AJ, Paton JC (2011) Contribution of Serotype and Genetic Background to Virulence of Serotype 3 and Serogroup 11 Pneumococcal Isolates. *Infect Immun*.
- Titgemeyer F, Reizer J, Reizer A, Saier MH, Jr. (1994) Evolutionary relationships between sugar kinases and transcriptional repressors in bacteria. *Microbiology* 140(Pt 9): 2349–2354.
- Hanson SR, Best MD, Wong CH (2004) Sulfatases: structure, mechanism, biological activity, inhibition, and synthetic utility. *Angew Chem Int Ed Engl* 43: 5736–5763.
- Sardiello M, Annunziata I, Roma G, Ballabio A (2005) Sulfatases and sulfatase modifying factors: an exclusive and promiscuous relationship. *Hum Mol Genet* 14: 3203–3217.
- Landgrebe J, Dierks T, Schmidt B, von Figura K (2003) The human SUMF1 gene, required for posttranslational sulfatase modification, defines a new gene family which is conserved from pro- to eukaryotes. *Gene* 316: 47–56.
- Morona JK, Morona R, Paton JC (2006) Attachment of capsular polysaccharide to the cell wall of *Streptococcus pneumoniae* type 2 is required for invasive disease. *Proc Natl Acad Sci U S A* 103: 8505–8510.
- Shafeeq S, Kloosterman TG, Kuipers OP (2011) CelR-mediated activation of the cellobiose-utilization gene cluster in *Streptococcus pneumoniae*. *Microbiology* 157: 2854–2861.
- Carlson BL, Ballister ER, Skordalakes E, King DS, Breidenbach MA, et al. (2008) Function and structure of a prokaryotic formylglycine-generating enzyme. *J Biol Chem* 283: 20117–20125.
- Giammarinaro P, Paton JC (2002) Role of RegM, a homologue of the catabolite repressor protein CcpA, in the virulence of *Streptococcus pneumoniae*. *Infect Immun* 70: 5454–5461.
- Iyer R, Baliga NS, Camilli A (2005) Catabolite control protein A (CcpA) contributes to virulence and regulation of sugar metabolism in *Streptococcus pneumoniae*. *J Bacteriol* 187: 8340–8349.
- Higgins MA, Whitworth GE, El Warry N, Randrianosa M, Samain E, et al. (2009) Differential recognition and hydrolysis of host carbohydrate-antigens by *Streptococcus pneumoniae* family 98 glycoside hydrolases. *J Biol Chem*.
- Hooper LV, Manzella SM, Baenziger JU (1996) From legumes to leukocytes: biological roles for sulfated carbohydrates. *FASEB J* 10: 1137–1146.
- Honke K, Taniguchi N (2002) Sulfotransferases and sulfated oligosaccharides. *Med Res Rev* 22: 637–654.
- Yu H, Chen X (2007) Carbohydrate post-glycosylational modifications. *Org Biomol Chem* 5: 865–872.
- Dutta PK, Dutta J, Tripathi VS (2004) Chitin and chitosan: Chemistry, properties and applications. *J Sci and Ind Res* 63: 20–31.
- Martin B, Garcia P, Castanic MP, Claverys JP (1995) The *recA* gene of *Streptococcus pneumoniae* is part of a competence-induced operon and controls lysogenic induction. *Mol Microbiol* 15: 367–379.
- Trappetti C, Kadioglu A, Carter M, Hayre J, Iannelli F, et al. (2009) Sialic acid: a preventable signal for pneumococcal biofilm formation, colonization, and invasion of the host. *J Infect Dis* 199: 1497–1505.
- Horton RM, Ho SN, Pullen JK, Hunt HD, Cai Z, et al. (1993) Gene splicing by overlap extension. *Methods Enzymol* 217: 270–279.
- Lee J, Lee HJ, Shin MK, Ryu WS (2004) Versatile PCR-mediated insertion or deletion mutagenesis. *Biotechniques* 36: 398–400.
- Standish AJ, Strocher UH, Paton JC (2005) The two-component signal transduction system RR06/HK06 regulates expression of *cbpA* in *Streptococcus pneumoniae*. *Proc Natl Acad Sci U S A* 102: 7701–7706.
- LeMessurier KS, Ogunniyi AD, Paton JC (2006) Differential expression of key pneumococcal virulence genes in vivo. *Microbiology* 152: 305–311.
- Mahdi LK, Ogunniyi AD, LeMessurier KS, Paton JC (2008) Pneumococcal virulence gene expression and host cytokine profiles during pathogenesis of invasive disease. *Infect Immun* 76: 646–657.
- Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2^{(-Delta Delta C(T))} Method. *Methods* 25: 402–408.
- McAllister IJ, Tseng H-J, Ogunniyi AD, Jennings MP, McEwan AG, et al. (2004) Molecular analysis of the *psa* permease complex of *Streptococcus pneumoniae*. *Mol Microbiol* 53: 889–901.
- Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res* 25: 3389–3402.
- Saier MH, Jr., Tran CV, Barabote RD (2006) TCDB: the Transporter Classification Database for membrane transport protein analyses and information. *Nucleic Acids Res* 34: D181–186.
- Finn RD, Mistry J, Tate J, Coghill P, Heger A, et al. (2010) The Pfam protein families database. *Nucleic Acids Res* 38: D211–222.
- Soding J, Biegert A, Lupas AN (2005) The HHPred interactive server for protein homology detection and structure prediction. *Nucleic Acids Res* 33: W244–248.

Author Contributions

Conceived and designed the experiments: LJM ADO UHS JCP. Performed the experiments: LJM. Analyzed the data: LJM ADO UHS JCP. Wrote the paper: LJM ADO UHS JCP.